Boysen Bio ApS: Financial statements 2022
CVR: 38655590
Source: annual report 2022, Danish Business Authority
01/07/2021 – 30/06/2022
Boysen Bio ApS (CVR 38655590) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -5,014 and a net result of DKK -5,062 compared with DKK -4,039 the year before. Equity in the 2022 report amounted to DKK 56,276. The solvency ratio was 14.9%.
- Gross Profit
- DKK -5,014
- Profit/Loss
- DKK -5,062
- Equity
- DKK 56,276
- Total Assets
- DKK 376,485
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -5 t. | -5 t. | 56 t. | - |
| 2021 | - | -4 t. | -4 t. | 21 t. | - |
| 2020 | - | -4 t. | -4 t. | 25 t. | - |
| 2019 | - | -9 t. | -18 t. | 29 t. | - |
Official annual report
Keep an eye on Boysen Bio ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout Boysen Bio ApS
Boysen Bio ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2017. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named Boysen Bio IVS and GlyProVac IVS. The management consists of Anders Boysen. The company is owned by Anders Boysen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -4,142 and a net result of DKK -4,142 compared with DKK -4,968 the year before. Equity in the 2025 report amounted to DKK 42,055.